Hereditary spastic paraplegia with SPG30 mutation: A report from North East China

Chunkui Zhou, Lijun Zhu, Xinyuan Li, Heqian Du, Shanshan Dong, Qun Liu, Shaokuan Fang

Department of Neurology, Neuroscience Centre, the First Teaching Hospital of Jilin University, Changchun; The Third Teaching Hospital of Jilin University, Changchun, China

Abstract

Hereditary spastic paraplegia is a heterogeneous group of genetic neurodegenerative disorders of the nervous system. It is classified into four subtypes based on the mode of inheritance; and among them, most autosomal recessive hereditary spastic paraplegia cases are due to type SPG11 and SPG15 gene mutations. Autosomal recessive hereditary spastic paraplegia cases with SPG30 gene mutation have never been reported in China. Herein, we present our experience with a case of hereditary spastic paraplegia with SPG30 gene mutation in our hospital from North East China. In this patient we detected a missense mutation of c.499 C>T (p.Arg167Cys) in gene KIF1A, a causative gene of type SPG30.

Key Words: Hereditary spastic paraplegia, SPG30, KIF1A

INTRODUCTION

Hereditary spastic paraplegia (HSP) is a heterogeneous group of genetic neurodegenerative disorders that affects the nervous system. Clinically, the disease manifests as progressive spastic paraplegia. Pathologically, the disease is characterized by degeneration and/or demyelination of bilateral corticospinal tract. HSP is classified into four subtypes based on the mode of inheritance: autosomal dominant HSP (AD-HSP), autosomal recessive HSP (AR-HSP), X-linked HSP (XL-HSP) and HSP with maternally inherited characteristics. Most AR-HSP cases are due to type SPG11 and SPG15 gene mutations. AR-HSP cases with SPG30 gene mutation have never been reported in China. Here, we present a HSP patient with SPG30 gene mutation presented to our Hospital in Jilin, North East China.

CASE REPORT

A 16-year-old Han male middle school student was referred to our hospital with a history of progressive gait difficulties over the past 4 years. Initially the patient had stiffness of the lower limbs and had to drag his feet while walking. At the onset of the illness, there was no muscle weakness. His parents did not have a consanguineous marriage. There was no other significant past medical history, such as trauma or surgery. There was also no family history of similar illness, or epilepsy. On physical examination, the patient had normal mentation, the cranial nerve examination was also normal. There was no muscle atrophy, the muscle strength in his upper extremities was normal (Medical Research Council --MRC grade V). The upper limbs muscle tone was normal, whereas hypertonia was observed in both lower limbs. Deep tendon reflexes of the upper and lower limbs were brisk. Ankle clonus could be elicited both sides. Babinski and Chaddock signs were bilaterally extensor. He could not walk on a straight line. Romberg’s sign was negative. There were no deficits of superficial or deep sensation, and no ataxia. The brain stem evoked potential was normal; EMG results were suggestive of damage to sensory nerve fibers in both legs. No obvious abnormalities were observed on magnetic resonance imaging (MRI) study of brain and spinal cord.

High-throughput sequencing was performed to assess mutations of genes related to HSP. These included, PLP1, ATL1, SPAST, CYP7B1, NIPA1, SPG7, KIAA0196, KIF5A, KIAA1840, RTN2, HSPD1, ZFYVE26, ERLIN2, KIF1A, REEP1, ZFYVE27, FA2H, PNPLA6, SLC33A1, GJC2, AP4B1, AP5Z1, AP4M1, AP4E1 and AP4S1. Suspected mutation sites were found in gene KIF1A, with c.499 C>T, p.Arg167Cys revealed by Sanger sequencing (Figure 1). Results were
Neurology Asia June 2017

analyzed in ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/), with a previous report on c.499 C>T, p.Arg167Cys in gene KIF1A, which was thought to be the possible cause of spastic paraplegia.5

The patient was diagnosed as HSP based on history, clinical findings and investigations. Oral baclofen therapy was prescribed at initial dosage of 5 mg tid. The muscle tone of lower limbs improved slightly. Physiotherapy was also given.

DISCUSSION

HSP is a rare hereditary neurodegenerative disease that can be categorized as simple or complex types according to the clinical manifestations.1 HSP is marked by significant genetic heterogeneity. It is caused by the mutation of genes encoding proteins that maintain the functions of corticospinal tract in the spinal cord.6 Mutation sites have been localized in nearly 60 genes.7 Nineteen HSP genes are related to AD-HSP; 34 are related to AR-HSP; 5 to X-linked XL-HSP, and one gene is related to SP with maternally inherited characteristics. In this patient we detected a missense mutation of c.499 C>T (p.Arg167Cys) in gene KIF1A, a causative gene of type SPG30, which is seen in AR-HSP. The characterization of this gene mutation remains poor. AR-HSP cases with SPG30 gene mutation have never been reported in China. Klebe et al.8 reported one pedigree of SPG30 gene mutation in eastern France, whose family was originally from Algeria. A total of four family members were affected. Their clinical manifestations included spastic paraparesis, peripheral neuropathy and mild cerebellar symptoms. Computed tomography (CT) revealed cerebellar atrophy, which was probably the cause of the mild cerebellar symptoms. In another report, Lee et al. identified a de novo missense mutations in KIF1A in 13 patients. These mutations were present in the blood DNA of the probands but not in the parents. These heterozygous KIF1A mutations included c.499C>T(p.R167C).9 The report also mentioned that de novo missense mutation in the motor domain of KIF1A causes a phenotype being more severe than recessive mutations in the same gene. The difference between our case and the case in the report is that our patient has a simple HSP phenotype.

The pathogenic gene for SPG30 is located on chromosome 2q37.3, which is known to encode for protein kinesin 3.3 Genetic testing of this patient revealed a missense mutation of c.499C>T for the 167th codon. However, genetic testing of samples from his parents and sister showed no mutation of this gene, which suggest de novo missense mutation of this HSP case of an unknown etiology. The patient was diagnosed as a case of pure HSP based on the clinical manifestations of spastic paraplegia, with normal brain stem evoked potential.

The pathogenesis of HSP remains unknown. Deranged myelin formation, mitochondrial respiratory chain dysfunction, axonal transport interruption, cytoskeleton damage and vesicular transport blockade are believed to contribute to the axonal degeneration.10 No effective therapeutic modalities are currently available.

In our patient, the hypertonic lower limbs did not respond to baclofen therapy in the first month, which required an increase in its dosage. Physiotherapy was administered as supportive treatment. Currently available treatment modalities only provide symptomatic relief and improve the patient’s quality of life with no effect on the clinical course of the disease. Gene therapy tailor-made for each of these diseases may be the future therapeutic option.

DISCLOSURE

Financial support: None
Conflict of interest: None

REFERENCES


